Table 3.
Patient Characteristics by HER2 Status Following Trastuzumab Containing Primary Chemotherapy
| HER2 not Amplified | HER2 Amplified | p-value | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| 8 | 17 | ||||
| Race | |||||
| Black | 1 | 12.5% | 3 | 17.7% | |
| Spanish/Hispanic | 2 | 25.0% | 3 | 17.7% | |
| White | 5 | 62.5% | 11 | 64.7% | 1 |
| Age at diagnosis, years | |||||
| Min | 40 | -- | 30 | -- | |
| Median | 49 | -- | 50 | -- | |
| Max | 67 | -- | 61 | -- | 0.777 |
| Histology | |||||
| Ductal | 7 | 87.5% | 14 | 82.3% | |
| Other | 1 | 12.5% | 3 | 17.7% | 1 |
| Clinical T Stage | |||||
| T1 | 1 | 12.5% | 3 | 17.7% | |
| T2 | 3 | 37.5% | 7 | 41.2% | |
| T3 | 0 | 0.0% | 5 | 29.4% | |
| T4 | 4 | 50.0% | 2 | 11.8% | 0.143 |
| Clinical N Stage | |||||
| N0 | 2 | 25.0% | 6 | 35.3% | |
| N1 | 2 | 25.0% | 9 | 52.9% | |
| N3 | 4 | 50.0% | 2 | 11.8% | 0.186 |
| Clinical Stage | |||||
| I | 0 | 0.0% | 1 | 5.9% | |
| II | 3 | 37.5% | 9 | 52.9% | |
| III | 5 | 62.5% | 7 | 41.2% | 0.774 |
| Nuclear Grade | |||||
| II | 2 | 25.0% | 5 | 29.4% | |
| III | 6 | 75.0% | 12 | 70.6% | 1 |
| LVI | |||||
| Positive | 3 | 37.5% | 5 | 29.4% | |
| Negative | 5 | 62.5% | 12 | 70.6% | 1 |
| ER | |||||
| Positive | 2 | 25.0% | 12 | 70.6% | |
| Negative | 6 | 75.0% | 5 | 29.4% | 0.081 |
| PR | |||||
| Positive | 2 | 25.0% | 11 | 64.7% | |
| Negative | 6 | 75.0% | 6 | 35.3% | 0.097 |
Abbreviations: LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor.